Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report.
Purpose. To associate baseline patient characteristics and relapse across consecutive COG studies. Methods. We analyzed risk factors for LESFT patients in three randomized COG trials. We evaluated age at enrollment, primary site, gender, tumor size, and treatment (as randomized). We estimated event-free survival (EFS, Kaplan-Meier) and compared risk across groups (log-rank test). Characteristics were assessed by proportional hazards regression with the characteristic of interest as the only component. Confidence intervals (CI) for RR were derived. Factors related to outcome at level 0.05 were included in a multivariate regression model. Results. Between 12/1988 and 8/2005, 1444 patients were enrolled and data current to 2001, 2004, or 2008 were used. Patients were with a median age of 12 years (0-45), 55% male and 88% Caucasian. The 5-year EFS was 68.3% ± 1.3%. In univariate analysis age, treatment, and tumor location were identified for inclusion in the multivariate model, and all remained significant (p < 0.01). Since tumor size was not collected in the last study, the other two were reanalyzed. This model identified age, treatment, tumor location, and tumor size as significant predictors. Conclusion. Age > 18 years, pelvic tumor, size > 8 cms, and chemotherapy without ifosfamide/etoposide significantly predict worse outcome. AEWS0031 is NCT00006734, INT0091 and INT0054 designed before 1993 (unregistered).
Department of Pediatrics, Stanford University and Lucile Packard Children's Hospital, 1000 Welch Road, Suite 300, Palo Alto, CA 94304-1812, USA.
Neyssa
N
Marina
Department of Pediatrics, New York University, Langone Medical Center, New York, NY 10016, USA.
Linda
L
Granowetter
Pediatric Hematology-Oncology, Dana Farber & Boston Children's Hospital, 44 Binney Street, Boston, MA 02115, USA.
Holcombe E
HE
Grier
Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Richard B
RB
Womer
Sarcoma Services, Huntsman Cancer Institute and Primary Children's Medical Center Department of Orthopaedics, University of Utah, Salt Lake City, UT 84112, USA.
R Lor
RL
Randall
Department of Radiation Oncology, Boston Children's Hospital/Dana Farber Cancer Institute Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Karen J
KJ
Marcus
Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90027, USA ; Children's Oncology Group Statistics, Monrovia, CA 91016, USA.
Elizabeth
E
McIlvaine
Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90027, USA ; Children's Oncology Group Statistics, Monrovia, CA 91016, USA.
Mark
M
Krailo